A significant body of work predicts inhibition of the IGF1R to have anti-neoplastic effects yet such promise has not translated in to success in clinical trials, including that of the IGF1R antibody figitumumab in patients with advanced NSCLC [41], [62]. Here, IGF1R is linked to non-small cell lung carcinoma.